ICORG has had an abstract accepted for ESMO 2012 on "Serum levels of VEGF pre- and post-treatment with bevacizumab for early stage breast cancer" [ICORG 08-10 Study].
The ESMO Congress will occur in Vienna, Austria from 28 September to 2 October.
ICORG has had an abstract accepted for ESMO 2012 on "Serum levels of VEGF pre- and post-treatment with bevacizumab for early stage breast cancer" [ICORG 08-10 Study].
The ESMO Congress will occur in Vienna, Austria from 28 September to 2 October.